Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. gained 1.740% today.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 7 € there is a slightly positive potential of 10.85% for Xeris Biopharma Holdings Inc. compared to the current price of 6.32 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.740% | 2.184% | 1.937% | 92.648% | 92.648% | 441.502% | 44.839% |
| Ardelyx Inc. | -1.080% | -0.244% | -3.002% | -1.067% | -1.067% | 106.821% | -14.929% |
| Krystal Biotech | 0.970% | 0.790% | 14.648% | 42.444% | 42.444% | 189.067% | - |
| Evolus Inc | -4.390% | -3.390% | -4.202% | -45.714% | -45.714% | -16.788% | 115.176% |
Comments
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat